Management of Immune-Related Toxicities in Melanoma Has Improved Over Time
Source: Targeted Oncology, April 2024
During a Case-Based Roundtable® event, Evan J. Lipson, MD, discussed with participants how their experience with immunotherapy toxicities has changed over time in the first article of a 2-part series.
DISCUSSION QUESTIONS
Discuss your comfort level in managing immune-related adverse events (AEs) in the setting of metastatic melanoma. How has this changed over time? ?
To what extent does ease/difficulty of managing potential toxicities factor into your recommendations??
EVAN LIPSON, MD: There’s a different feel for some of the immunotherapies [IOs] now, and…we as a group may be better at managing some of the toxicity. I’m interested if anybody has opinions about that. Dr Sawhney, are we better at managing toxicity now than we were 5 years ago?